Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes    » A1c    » Adolescents    » Awareness    » Cause    » Children    » Complications    » Control    » Costs    » Cure    » Diagnosis    » Drugs    » Elderly    » Gestational    » Hypoglycemia    » Impaired Fasting Glucose    » Impaired Glucose Tolerance    » Inflammation    » Insulin Resistance    » Insulin Sensitivity    » Men    » Metabolic Syndrome    » Minorities    » Obesity    » Organs    » Other Diseases    » Pancreas    » Pre-Diabetes    » Prevention    » Research    » Risk Factors    » Screening    » Statistics    » Stress    » Syndrome X    » Testing    » Treatments    » Type 1    » Type 2    » Warning Signs    » Women Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

About Diabetes » Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Pres. Bush Veto’s Bill To Further Embryonic Stem-Cell Research Posted: Friday, July 28, 2006

Speaking in Washington, President Bush declared that the proposed law would have supported ' the taking of innocent human life in the hope of finding medical benefits for others and it crosses a real moral boundary that our society needs to respect.'

Once A Day Insulin As Effective as Multiple Injections For Type 2’s Posted: Friday, July 21, 2006

Patients with type 2 diabetes may be able to achieve the same glucose control with fewer injections a day.

Atorvastatin Lowers Cholesterol, But Does Not Prevent Cardiac Events in Diabetic Posted: Friday, July 21, 2006

Although atorvastatin therapy led to a significant reduction in mean LDL cholesterol level in patients with type 2 diabetes, there was no significant difference from placebo in cardiac events, such as cardiovascular death and myocardial infarction (MI).

Evening and Bedtime Second Dose Equal for Long-Acting Insulin Levemir Posted: Friday, July 14, 2006

Patients who take Levemir (insulin detemir) twice daily can chose a convenient evening time for their second dose.

Exenatide Reduces Insulin Use in Type 2 Diabetics Posted: Friday, July 07, 2006

Exenatide therapy results in weight loss and a substantial decrease in insulin doses in some of the most difficult-to-manage patients with type 2 diabetes.

Metformin Induces Long-Term Weight Loss in Teens Posted: Friday, July 07, 2006

Metformin can induce long-term weight loss in obese, non-diabetic adolescents, and could possibly be useful in a regimen to help achieve weight loss in adolescents, who may have developed type 2 diabetes type due to overweight.

Report: Gardenia Fruit Compound Starting Point For Diabetes Therapy Posted: Friday, June 30, 2006

A Gardenia fruit extract traditionally used in Chinese medicine to treat the symptoms of type 2 diabetes does indeed contain a chemical that reverses some of the pancreatic dysfunctions that underlie the disease, researchers report in the June 7, 2006, Cell Metabolism. The chemical therefore represents a useful starting point for new diabetes therapies, they said.

New Agent Reduces Risk of Diabetic Retinopathy Posted: Friday, June 23, 2006

A protein kinase C-beta inhibitor reduced the risk of sustained vision loss and progression of diabetic macular edema in two phase III trials, researchers announced.

New Drug Galvus Lowers A1c 2.8% Posted: Friday, June 23, 2006

Galvus, a new once-daily oral treatment option for type 2 diabetes, lowers A1c 2.8% and demonstrates impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.

Pfizer, Bayer Partner on Fat Modifier Obesity Drugs Posted: Friday, June 23, 2006

Pfizer is buying exclusive worldwide rights to an experimental class of Bayer obesity drugs.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.